N/A N=28 Youth Ending the HIV Epidemic
HIV/AIDS · Mobile Health · Young Adults
Primary: Feasibility: Rate of Participant Retention — 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,911 Data-informed Stepped Care (DiSC) to Improve Adolescent HIV Outcomes (UH3)
Adolescent Behavior · Hiv
Primary: Proportion of Missed Visits — 406; 433 Scheduled visits — p=0.631
N/A N=1,066 Adolescent Transition To Adult Care for HIV-infected Adolescents in Kenya
Adolescent Behavior · HIV · Transition
Primary: Transition Readiness Score Overall — 15.7; 13.9 score on a scale
Phase 3 N=50 Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL
Phase 2 N=78 An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)
HIV Infection
Primary: Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study — 0 Participants
N/A N=1,988 Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa
HIV
Primary: Effectiveness of SEARCH Youth Intervention — 88.2; 80.5; 90.9; 85.3 % of participants — p=0.0019
N/A N=41 Youth Power Action Feasibility Study of Online Support Group Intervention Among Adolescents Living With HIV in Nigeria
HIV/AIDS · Adolescent Behavior · Medication Adherence
Primary: Percentage of Active Members Who Have at Least One Post in Group Chat Session. — 32 Participants
N/A N=212 A Risky Sex Prevention Intervention for Middle School Age Minority Girls
HIV · Risky Sex Prevention
Primary: Adolescent Sexual Activity Index — 1.39; 1.45; 2.12; 1.90 score on a scale — p=0.62
Phase 2 N=55 Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
HIV Infections
Primary: Count and Percentage of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities Among Participants Who Receive at…
N/A N=80 InTSHA: Interactive Transition Support for HIV-infected Adolescents Using Social Media
HIV-1-infection · Adolescent Behavior
Primary: Acceptability of Intervention Measure Score — 4.1 score on a scale
N/A N=515 Prospective Cohort Study of Adolescents Living With HIV and Their Caregivers Attending a Psychosocial Programme in Botswana
Hiv
Primary: Quality of Life/Well-being (Young People) — 4.77 score on a scale
Phase 3 N=87 Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
HIV Infections
Primary: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA — -1.580; -1.549 log10 copies/mL — p=0.55
N/A N=102 Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)
HIV Infections
Primary: Difference in CD4+ T Cell Percentage Between Week 0 and Week 48 — -10.08 percentage of CD4+ T cells — p=<0.0001
N/A N=60 Adherence Connection for Counseling, Education, and Support (ACCESS) II
HIV Infections
Primary: Self-Reported ART Adherence — 56.67; 58.7 Percentage of successful doses
N/A N=662 Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents
HIV Infections · Sexually Transmitted Diseases
Primary: Self-report of Ever Having Sexual Intercourse — 39; 40; 44; 31 Participants — p=.03
Phase 2 N=9 Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
HIV Infections
Primary: Safety Endpoint: Proportion of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities Among Participants Who Receive…
Phase 2 N=96 Study of Dapivirine Vaginal Ring (VR) in Adolescents
Human Immunodeficiency Virus
Primary: The Safety of Dapivirine (25 mg) Administered Via a Silicone Vaginal Ring in HIV-uninfected Adolescent Females, When Inserted Once Every 4 Weeks During 24 Weeks of Study…
N/A N=65 PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS
HIV/AIDS
Primary: CD4 Cell Count — 996; 1049 cells/mm^3
N/A N=222 Reducing HIV Risk Among Adolescents: Evaluating Project HEART
HIV · Sexually Transmitted Diseases
Primary: 6-item Self-report of Program Acceptability — 84; 94; 101; 60 Participants
N/A N=226 Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens
HIV Infections · Sexually Transmitted Diseases
Primary: Acceptability — 88; 83 Participants
Phase 3 N=60 Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
HIV
Primary: Incidence of Treatment-Emergent Serious Adverse Events — 4.0; 0 percentage of participants
N/A N=125 Digital Star: HIV Prevention for Youth in Mental Health Treatment
Human Immunodeficiency Virus · Mental Health
Primary: HIV Knowledge — 11.10; 10.98 score on a scale
N/A N=1,095 Adolescent Wellness Visits in Tanzania
HIV Testing · Contraceptive Usage
Primary: Number of Adolescents Who Self-reported HIV Testing and Counseling, Inclusive of the Adolescent Wellness Visit — 234; 86 Participants
Phase 2 N=148 Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents
HIV Infections
Primary: The Percentage of Participants Who Report Willingness to Use the Study Regimen, Take up PrEP, and Remain on PrEP as Part of a Comprehensive Prevention Package — 148…
N/A N=183 Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Human Immunodeficiency Virus · Immune Reconstitution Inflammatory Syndrome
Primary: All-cause Mortality — 21; 18 participants
N/A N=89 Suubi4Stigma: Addressing HIV-Associated Stigma Among Adolescents
HIV/AIDS
Primary: HIV Stigma (Child Reports) — 75.07; 73.0; 75.29 score on a scale
Phase 3 N=32 Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48 — 81…
N/A N=59 A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA
Sexually Transmitted Infection · Hiv
Primary: Number of AGYW Who Tested Positive for a Sexually Transmitted Infection (STI) — 4; 6 Participants — p=0.15
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Phase 2 N=52 T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
HIV Infections
Primary: Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343) — 56.1; 52.7; 3.07; 3.41 microgram hour per…